A Phase 3 interventional study of 10mg Rosuvastatin and Placebo in Renal Failure, sponsored by AstraZeneca. Completed at 241 sites in 25 countries. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-05-19.
Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Renal Insufficiency by AstraZeneca — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · AstraZeneca.
Among the 29 studies in Renal Insufficiency by AstraZeneca, this one has the largest enrollment, is the only one that started in 2003, is one of 2 in phase 3, and was the 1st registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →None of the 29 studies in Renal Insufficiency by AstraZeneca is open now. The open studies under Renal Insufficiency, anywhere →
Of the 93 Renal Insufficiency studies recruiting now, 49 (53%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,776 is above the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 24 across the 29 interventional studies. Of the 29 that completed or were terminated, 4 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Renal Insufficiency by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: 10mg Rosuvastatin
matching Placebo
Drug: Placebo
Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death)
Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Number of Randomised Participants That Died From Any Cause.
Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Number of Randomised Participants With a Major Cardiovascular Event or That Died From Any Known Cause
Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Number of Randomised Participants That Died From Cardiovascular Cause
Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Number of Randomised Participants That Died From Non Cardiovascular Cause
Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Number of Randomised Participants With an Atherosclerotic Cardiac Event (Non-fatal Myocardial Infarction or Coronary Heart Disease (CHD) Death)
Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Number of Randomised Participants That Experienced a Procedure as a Result of Stenosis or Thrombosis of the Vascular Access (Arteriovenous (AV) Fistulas and Grafts Only) for Haemodialysis.
Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Number of Randomised Participants That Experienced a Coronary or Peripheral Revascularisation (Including Above Ankle Limb Amputations).
Time frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years
Recruited patients were male or female with end-stage renal failure aged 50 to 80 years, who had received regular chronic haemodialysis treatment (including haemofiltration and hemodiafiltration ) for at least 3 months. They were recruited from 280 sites in 25 countries; recruitment started on 16 January 2003 and finished on 24 November 2004.
| Milestone | Rosuvastatin 10mg | Placebo |
|---|---|---|
| Started | 1389 | 1384 |
| Completed | 1263 | 1250 |
| Not completed | 126 | 134 |
| Withdrew: Withdrawal by subject | 125 | 132 |
| Withdrew: Option selected by investigator | 1 | 2 |
| Participants | Rosuvastatin 10mg | Placebo |
|---|---|---|
| Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death) | 396 | 408 |
| Participants | Rosuvastatin 10mg | Placebo |
|---|---|---|
| Number of Randomised Participants That Died From Any Cause. | 636 | 660 |
| Participants | Rosuvastatin 10mg | Placebo |
|---|---|---|
| Number of Randomised Participants With a Major Cardiovascular Event or That Died From Any Known Cause | 614 | 645 |
| Participants | Rosuvastatin 10mg | Placebo |
|---|---|---|
| Number of Randomised Participants That Died From Cardiovascular Cause | 324 | 324 |
Results for this outcome have not been posted.
| Participants | Rosuvastatin 10mg | Placebo |
|---|---|---|
| Number of Randomised Participants With an Atherosclerotic Cardiac Event (Non-fatal Myocardial Infarction or Coronary Heart Disease (CHD) Death) | 258 | 256 |
| Participants | Rosuvastatin 10mg | Placebo |
|---|---|---|
| Number of Randomised Participants That Experienced a Procedure as a Result of Stenosis or Thrombosis of the Vascular Access (Arteriovenous (AV) Fistulas and Grafts Only) for Haemodialysis. | 390 | 360 |
| Participants | Rosuvastatin 10mg | Placebo |
|---|---|---|
| Number of Randomised Participants That Experienced a Coronary or Peripheral Revascularisation (Including Above Ankle Limb Amputations). | 148 | 152 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin 10mg | — | — | 620/1,389 (44.6%) |
| Placebo | — | — | 635/1,378 (46.1%) |
| Event | Rosuvastatin 10mg | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 92/1389 | 96/1378 |
| SepsisInfections and infestations | 65/1389 | 70/1378 |
| Arteriovenous Fistula Site ComplicationInjury, poisoning and procedural complications | 54/1389 | 60/1378 |
| Myocardial InfarctionCardiac disorders | 53/1389 | 52/1378 |
| Arteriovenous Fistula ThrombosisInjury, poisoning and procedural complications | 53/1389 | 45/1378 |
| Atrial FibrillationCardiac disorders | 39/1389 | 45/1378 |
| Vascular Access ComplicationInjury, poisoning and procedural complications | 30/1389 | 40/1378 |
| Cardiac FailureCardiac disorders | 30/1389 | 35/1378 |
| Sudden DeathGeneral disorders | 33/1389 | 30/1378 |
| Angina PectorisCardiac disorders | 21/1389 | 31/1378 |
| Event | Rosuvastatin 10mg | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 202/1389 | 188/1378 |
| BronchitisInfections and infestations | 129/1389 | 133/1378 |
| Arteriovenous Fistula Site ComplicationInjury, poisoning and procedural complications | 131/1389 | 131/1378 |
| VomitingGastrointestinal disorders | 112/1389 | 127/1378 |
| NasopharyngitisInfections and infestations | 127/1389 | 116/1378 |
| CoughRespiratory, thoracic and mediastinal disorders | 120/1389 | 125/1378 |
| NauseaGastrointestinal disorders | 121/1389 | 97/1378 |
| HypotensionVascular disorders | 115/1389 | 109/1378 |
| HeadacheNervous system disorders | 109/1389 | 112/1378 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 110/1389 | 93/1378 |
| Age Continuous(Years) | Rosuvastatin 10mg | Placebo | Total |
|---|---|---|---|
| Mean | 64.1 ± 8.6 | 64.3 ± 8.7 | 64.2 ± 8.6 |
| Sex: Female, Male(Participants) | Rosuvastatin 10mg | Placebo | Total |
|---|---|---|---|
| Female | 538 | 512 | 1050 |
| Male | 851 | 872 | 1723 |
Showing the first 100 of 241 sites across 25 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2003, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin